2seventy bio Stock (NASDAQ:TSVT)
Previous Close
$4.40
52W Range
$1.53 - $6.40
50D Avg
$4.75
200D Avg
$4.65
Market Cap
$232.26M
Avg Vol (3M)
$296.71K
Beta
1.78
Div Yield
-
TSVT Company Profile
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
TSVT Performance
Peer Comparison
Ticker | Company |
---|---|
DICE | DICE Therapeutics, Inc. |
PLRX | Pliant Therapeutics, Inc. |
CGEM | Cullinan Oncology, Inc. |
ZNTL | Zentalis Pharmaceuticals, Inc. |
IOVA | Iovance Biotherapeutics, Inc. |
RCUS | Arcus Biosciences, Inc. |
DAWN | Day One Biopharmaceuticals, Inc. |
PHAT | Phathom Pharmaceuticals, Inc. |
STOK | Stoke Therapeutics, Inc. |
SRPT | Sarepta Therapeutics, Inc. |
RLAY | Relay Therapeutics, Inc. |
REPL | Replimune Group, Inc. |
KDNY | Chinook Therapeutics, Inc. |
SNDX | Syndax Pharmaceuticals, Inc. |
INZY | Inozyme Pharma, Inc. |
CRNX | Crinetics Pharmaceuticals, Inc. |
ASND | Ascendis Pharma A/S |
PBYI | Puma Biotechnology, Inc. |
MRSN | Mersana Therapeutics, Inc. |
KZR | Kezar Life Sciences, Inc. |
PTGX | Protagonist Therapeutics, Inc. |